Iambic closed an oversubscribed financing round raising more than $100 million from a broad investor base including ARK and Regeneron Ventures. The San Diego AI‑driven biotech said it will use proceeds to advance multiple AI‑discovered therapeutic candidates and enable platform development and partnerships. Iambic recently signaled clinical activity for IAM1363 and disclosed collaborations—such as a drug‑supply collaboration with Jazz Therapeutics and access deals with Revolution Medicines—highlighting a commercial strategy that blends in‑house programs with partner-enabled studies. AI‑driven discovery platforms like Iambic’s NeuralPLexer aim to accelerate target identification and molecule design; the funding underlines investor appetite for platform‑based biotech.